

Melanoma	<i>In vitro</i> mitotic index	IL-17A	IFN- γ	IL-6	IL-10	TNF-a	IL-12p40
B16.F10-NV	2 ± 0.1	6.47± 0.2	5.1± 0.1	37.4± 0.5	30.1± 0.5	12.25± 0.1	2.1 ± 0.1
B16.F10-GNP	2 ± 0.1	6.22 ± 0.1	5.2 ± 0.1	36.9 ± 0.4	30.3 ± 0.2	12.1 ± 0.2	2.0 ± 0.1
B16.F10-LLO ₉₁₋₉₉	2 ± 0.1	6.32 ± 0.3	5.3 ± 0.1	37.1 ± 0.3	31.1 ± 0.5	12.3 ± 0.2	2.1 ± 0.2
B16.F10-GNP-LLO ₉₁₋₉₉	0.2 ± 0.1	18.2 ± 0.3	54.2 ± 0.3	4.2 ± 0.5	3.2 ± 0.3	28.5 ± 0.5	8.2 ± 0.3
B16OVA-NV	0.8 ± 0.1	25.35 ± 0.1	6.2± 0.1	59.5± 0.3	8.3± 0.3	11.3 ± 0.2	1.95 ± 0.1
B16OVA-GNP	0.8 ± 0.1	24.5 ± 0.4	6.1 ± 0.1	58.2 ± 0.5	8.1 ± 0.2	11.0 ± 0.5	1.85 ± 0.1
B16OVA-LLO ₉₁₋₉₉	0.8 ± 0.1	25.1 ± 0.3	6.2 ± 0.2	59.0 ± 0.5	8.2 ± 0.3	11.2 ± 0.3	1.80 ± 0.1
B16OVA-GNP-LLO ₉₁₋₉₉	0.01 ± 0.05*	50.2 ± 0.5	95.5 ± 0.5	4.52 ± 0.1	0 ± 0	34.5 ± 0.3	12.08±0.1
CONTROL	NA	3.5±0.1	2.3± 0.2	3± 0.2	2.3± 0.1	2.1± 0.1	0.4 ± 0.1

Table S1.- Cytokine profile in sera of murine melanoma models vaccinated with control GNP, LLO₉₁₋₉₉, GNP-LLO₉₁₋₉₉ or non-vaccinated (NV). B16.F10 is a metastatic melanoma model with high mitotic index, while B16OVA derived from B16.F1 murine melanoma is a primary melanoma model with low mitotic index. Results are expressed as the mean ± SD. (P < 0.5). *(P < 0.05).